Empiric weight-based vancomycin in intensive care unit patients with methicillin-resistant Staphylococcus aureus bacteremia

Carlos A. Alvarez, Christopher A. Giuliano, Krystal K. Haase, Kathleen A. Thompson, Christopher R. Frei, Nicolas A. Forcade, Sara D. Brouse, Eric M. Mortensen, Todd Bell, Roger J. Bedimo, Nolan M. Toups, Ronald G. Hall

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Background: Previous studies were conducted in all hospitalized patients with methicillin-resistant Staphylococcus aureus (MRSA) bacteremia to determine safety and effectiveness of guidelinerecommended, weight-based dosing of vancomycin. In these studies, it was observed that severely ill patients (Pitt bacteremia score ≥4 or intensive care unit [ICU] patients) were at an increased risk of mortality and/or nephrotoxicity. Therefore, a subanalysis of the effect of guidelinerecommended vancomycin dosing on in-hospital mortality and nephrotoxicity in ICU patients with MRSA bacteremia was conducted.

Methods: This multicenter, retrospective, cohort study was conducted in a subset of ICU patients from a previous MRSA bacteremia study. Patients were ≥18 years old and received ≥48 hours of empiric vancomycin from July 1, 2002, to June 30, 2008. The incidence of nephrotoxicity and in-hospital mortality was compared in patients who received guideline-recommended dosing (at least 15 mg/kg per dose) to patients who received non-guideline-recommended dosing of vancomycin. Multivariable generalized linear mixed-effects models were constructed to determine independent risk factors for in-hospital mortality and nephrotoxicity.

Results: Guidelinerecommended dosing was received by 34% of patients (n 5 137). Nephrotoxicity occurred in 35% of patients receiving guidelinerecommended dosing and 39% receiving non-guideline-recommended dosing (P 5 0.67). In-hospital mortality rate was 24% among patients who received guideline-recommended dosing compared with 31% for non-guideline-recommended dosing (P 5 0.40). Guidelinerecommended dosing was not associated with nephrotoxicity (odds ratio: 1.10; 95% confidence interval: 0.43-2.79) or in-hospital mortality (odds ratio: 0.54; 95% confidence interval: 0.22-1.36) in the multivariable analysis.

Conclusions: Guideline-recommended dosing of vancomycin in ICU patients with MRSA bacteremia is not significantly associated with nephrotoxicity or in-hospital mortality. However, the 7% absolute difference for in-hospital mortality suggests that larger studies are needed.

Original languageEnglish (US)
Pages (from-to)371-376
Number of pages6
JournalAmerican Journal of the Medical Sciences
Volume348
Issue number5
DOIs
StatePublished - 2014

Fingerprint

Vancomycin
Methicillin-Resistant Staphylococcus aureus
Bacteremia
Intensive Care Units
Weights and Measures
Hospital Mortality
Guidelines
Odds Ratio
Confidence Intervals
Mortality
Cohort Studies
Retrospective Studies
Safety

Keywords

  • ICU
  • MRSA
  • Nephrotoxicity
  • Vancomycin
  • Weight

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Alvarez, C. A., Giuliano, C. A., Haase, K. K., Thompson, K. A., Frei, C. R., Forcade, N. A., ... Hall, R. G. (2014). Empiric weight-based vancomycin in intensive care unit patients with methicillin-resistant Staphylococcus aureus bacteremia. American Journal of the Medical Sciences, 348(5), 371-376. https://doi.org/10.1097/MAJ.0000000000000262

Empiric weight-based vancomycin in intensive care unit patients with methicillin-resistant Staphylococcus aureus bacteremia. / Alvarez, Carlos A.; Giuliano, Christopher A.; Haase, Krystal K.; Thompson, Kathleen A.; Frei, Christopher R.; Forcade, Nicolas A.; Brouse, Sara D.; Mortensen, Eric M.; Bell, Todd; Bedimo, Roger J.; Toups, Nolan M.; Hall, Ronald G.

In: American Journal of the Medical Sciences, Vol. 348, No. 5, 2014, p. 371-376.

Research output: Contribution to journalArticle

Alvarez, CA, Giuliano, CA, Haase, KK, Thompson, KA, Frei, CR, Forcade, NA, Brouse, SD, Mortensen, EM, Bell, T, Bedimo, RJ, Toups, NM & Hall, RG 2014, 'Empiric weight-based vancomycin in intensive care unit patients with methicillin-resistant Staphylococcus aureus bacteremia', American Journal of the Medical Sciences, vol. 348, no. 5, pp. 371-376. https://doi.org/10.1097/MAJ.0000000000000262
Alvarez, Carlos A. ; Giuliano, Christopher A. ; Haase, Krystal K. ; Thompson, Kathleen A. ; Frei, Christopher R. ; Forcade, Nicolas A. ; Brouse, Sara D. ; Mortensen, Eric M. ; Bell, Todd ; Bedimo, Roger J. ; Toups, Nolan M. ; Hall, Ronald G. / Empiric weight-based vancomycin in intensive care unit patients with methicillin-resistant Staphylococcus aureus bacteremia. In: American Journal of the Medical Sciences. 2014 ; Vol. 348, No. 5. pp. 371-376.
@article{10fb0f2af6694b6c8bcd0884c4f0b27c,
title = "Empiric weight-based vancomycin in intensive care unit patients with methicillin-resistant Staphylococcus aureus bacteremia",
abstract = "Background: Previous studies were conducted in all hospitalized patients with methicillin-resistant Staphylococcus aureus (MRSA) bacteremia to determine safety and effectiveness of guidelinerecommended, weight-based dosing of vancomycin. In these studies, it was observed that severely ill patients (Pitt bacteremia score ≥4 or intensive care unit [ICU] patients) were at an increased risk of mortality and/or nephrotoxicity. Therefore, a subanalysis of the effect of guidelinerecommended vancomycin dosing on in-hospital mortality and nephrotoxicity in ICU patients with MRSA bacteremia was conducted.Methods: This multicenter, retrospective, cohort study was conducted in a subset of ICU patients from a previous MRSA bacteremia study. Patients were ≥18 years old and received ≥48 hours of empiric vancomycin from July 1, 2002, to June 30, 2008. The incidence of nephrotoxicity and in-hospital mortality was compared in patients who received guideline-recommended dosing (at least 15 mg/kg per dose) to patients who received non-guideline-recommended dosing of vancomycin. Multivariable generalized linear mixed-effects models were constructed to determine independent risk factors for in-hospital mortality and nephrotoxicity.Results: Guidelinerecommended dosing was received by 34{\%} of patients (n 5 137). Nephrotoxicity occurred in 35{\%} of patients receiving guidelinerecommended dosing and 39{\%} receiving non-guideline-recommended dosing (P 5 0.67). In-hospital mortality rate was 24{\%} among patients who received guideline-recommended dosing compared with 31{\%} for non-guideline-recommended dosing (P 5 0.40). Guidelinerecommended dosing was not associated with nephrotoxicity (odds ratio: 1.10; 95{\%} confidence interval: 0.43-2.79) or in-hospital mortality (odds ratio: 0.54; 95{\%} confidence interval: 0.22-1.36) in the multivariable analysis.Conclusions: Guideline-recommended dosing of vancomycin in ICU patients with MRSA bacteremia is not significantly associated with nephrotoxicity or in-hospital mortality. However, the 7{\%} absolute difference for in-hospital mortality suggests that larger studies are needed.",
keywords = "ICU, MRSA, Nephrotoxicity, Vancomycin, Weight",
author = "Alvarez, {Carlos A.} and Giuliano, {Christopher A.} and Haase, {Krystal K.} and Thompson, {Kathleen A.} and Frei, {Christopher R.} and Forcade, {Nicolas A.} and Brouse, {Sara D.} and Mortensen, {Eric M.} and Todd Bell and Bedimo, {Roger J.} and Toups, {Nolan M.} and Hall, {Ronald G.}",
year = "2014",
doi = "10.1097/MAJ.0000000000000262",
language = "English (US)",
volume = "348",
pages = "371--376",
journal = "The American journal of the medical sciences",
issn = "0002-9629",
publisher = "Lippincott Williams and Wilkins",
number = "5",

}

TY - JOUR

T1 - Empiric weight-based vancomycin in intensive care unit patients with methicillin-resistant Staphylococcus aureus bacteremia

AU - Alvarez, Carlos A.

AU - Giuliano, Christopher A.

AU - Haase, Krystal K.

AU - Thompson, Kathleen A.

AU - Frei, Christopher R.

AU - Forcade, Nicolas A.

AU - Brouse, Sara D.

AU - Mortensen, Eric M.

AU - Bell, Todd

AU - Bedimo, Roger J.

AU - Toups, Nolan M.

AU - Hall, Ronald G.

PY - 2014

Y1 - 2014

N2 - Background: Previous studies were conducted in all hospitalized patients with methicillin-resistant Staphylococcus aureus (MRSA) bacteremia to determine safety and effectiveness of guidelinerecommended, weight-based dosing of vancomycin. In these studies, it was observed that severely ill patients (Pitt bacteremia score ≥4 or intensive care unit [ICU] patients) were at an increased risk of mortality and/or nephrotoxicity. Therefore, a subanalysis of the effect of guidelinerecommended vancomycin dosing on in-hospital mortality and nephrotoxicity in ICU patients with MRSA bacteremia was conducted.Methods: This multicenter, retrospective, cohort study was conducted in a subset of ICU patients from a previous MRSA bacteremia study. Patients were ≥18 years old and received ≥48 hours of empiric vancomycin from July 1, 2002, to June 30, 2008. The incidence of nephrotoxicity and in-hospital mortality was compared in patients who received guideline-recommended dosing (at least 15 mg/kg per dose) to patients who received non-guideline-recommended dosing of vancomycin. Multivariable generalized linear mixed-effects models were constructed to determine independent risk factors for in-hospital mortality and nephrotoxicity.Results: Guidelinerecommended dosing was received by 34% of patients (n 5 137). Nephrotoxicity occurred in 35% of patients receiving guidelinerecommended dosing and 39% receiving non-guideline-recommended dosing (P 5 0.67). In-hospital mortality rate was 24% among patients who received guideline-recommended dosing compared with 31% for non-guideline-recommended dosing (P 5 0.40). Guidelinerecommended dosing was not associated with nephrotoxicity (odds ratio: 1.10; 95% confidence interval: 0.43-2.79) or in-hospital mortality (odds ratio: 0.54; 95% confidence interval: 0.22-1.36) in the multivariable analysis.Conclusions: Guideline-recommended dosing of vancomycin in ICU patients with MRSA bacteremia is not significantly associated with nephrotoxicity or in-hospital mortality. However, the 7% absolute difference for in-hospital mortality suggests that larger studies are needed.

AB - Background: Previous studies were conducted in all hospitalized patients with methicillin-resistant Staphylococcus aureus (MRSA) bacteremia to determine safety and effectiveness of guidelinerecommended, weight-based dosing of vancomycin. In these studies, it was observed that severely ill patients (Pitt bacteremia score ≥4 or intensive care unit [ICU] patients) were at an increased risk of mortality and/or nephrotoxicity. Therefore, a subanalysis of the effect of guidelinerecommended vancomycin dosing on in-hospital mortality and nephrotoxicity in ICU patients with MRSA bacteremia was conducted.Methods: This multicenter, retrospective, cohort study was conducted in a subset of ICU patients from a previous MRSA bacteremia study. Patients were ≥18 years old and received ≥48 hours of empiric vancomycin from July 1, 2002, to June 30, 2008. The incidence of nephrotoxicity and in-hospital mortality was compared in patients who received guideline-recommended dosing (at least 15 mg/kg per dose) to patients who received non-guideline-recommended dosing of vancomycin. Multivariable generalized linear mixed-effects models were constructed to determine independent risk factors for in-hospital mortality and nephrotoxicity.Results: Guidelinerecommended dosing was received by 34% of patients (n 5 137). Nephrotoxicity occurred in 35% of patients receiving guidelinerecommended dosing and 39% receiving non-guideline-recommended dosing (P 5 0.67). In-hospital mortality rate was 24% among patients who received guideline-recommended dosing compared with 31% for non-guideline-recommended dosing (P 5 0.40). Guidelinerecommended dosing was not associated with nephrotoxicity (odds ratio: 1.10; 95% confidence interval: 0.43-2.79) or in-hospital mortality (odds ratio: 0.54; 95% confidence interval: 0.22-1.36) in the multivariable analysis.Conclusions: Guideline-recommended dosing of vancomycin in ICU patients with MRSA bacteremia is not significantly associated with nephrotoxicity or in-hospital mortality. However, the 7% absolute difference for in-hospital mortality suggests that larger studies are needed.

KW - ICU

KW - MRSA

KW - Nephrotoxicity

KW - Vancomycin

KW - Weight

UR - http://www.scopus.com/inward/record.url?scp=84914815036&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84914815036&partnerID=8YFLogxK

U2 - 10.1097/MAJ.0000000000000262

DO - 10.1097/MAJ.0000000000000262

M3 - Article

VL - 348

SP - 371

EP - 376

JO - The American journal of the medical sciences

JF - The American journal of the medical sciences

SN - 0002-9629

IS - 5

ER -